PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.

Michael E Stokes Veronica Calvo Sho Fujisawa Crissy Dudgeon Sharon Huang Nupur Ballal Leyi Shen Jennifer Gasparek Matthew Betzenhauser Simon J Taylor Kirk A Staschke Alan C Rigby Mark J Mulvihill Nandita Bose Eric S Lightcap David Surguladze

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

By disrupting an adaptive stress response evoked by VEGFR-TKIs, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard of care therapies in RCC.

Keyphrases

renal cell carcinoma
healthcare
palliative care
endoplasmic reticulum stress
induced apoptosis
quality improvement
vascular endothelial growth factor
pain management
endoplasmic reticulum
chronic myeloid leukemia